Artiva Biotherapeutics, Inc (ARTV)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

The chart shows the growth of an initial investment of $10,000 in Artiva Biotherapeutics, Inc, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.

Artiva Biotherapeutics, Inc (ARTV) has returned 50.12% so far this year and 114.67% over the past 12 months.

Based on dividend-adjusted daily data since Jul 19, 2024, ARTV's average daily return is +0.27%, while the average monthly return is +1.85%. At this rate, your investment would double in approximately 3.2 years.

Historically, 38% of months were positive and 62% were negative. The best month was Jul 2025 with a return of +98.7%, while the worst month was Jan 2025 at -49.6%. The longest winning streak lasted 2 consecutive months, and the longest losing streak was 7 months.

On a daily basis, ARTV closed higher 46% of trading days. The best single day was Oct 17, 2025 with a return of +117.0%, while the worst single day was Apr 8, 2025 at -42.0%.

Artiva Biotherapeutics, Inc has an annualized alpha of 65.55%, beta of 1.51, and R² of 0.03 versus S&P 500 Index. Calculated based on daily prices since July 22, 2024.

• This stock participated in 293.57% of S&P 500 Index downside but only 40.28% of its upside — more exposed to losses than it benefited from rallies.
• R² of 0.03 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

ARTV ranks 75 for risk / return — better than 75% of stocks on our site. You're getting solid returns for the risk taken. A good sign, especially for investors who want growth without excessive volatility.

The table below present risk-adjusted performance metrics for Artiva Biotherapeutics, Inc (ARTV) and compare them to a chosen benchmark (S&P 500 Index).

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Artiva Biotherapeutics, Inc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Artiva Biotherapeutics, Inc was 90.71%, occurring on Jun 27, 2025. The portfolio has not yet recovered.

The current Artiva Biotherapeutics, Inc drawdown is 59.32%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Artiva Biotherapeutics, Inc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Artiva Biotherapeutics, Inc is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.